Cited by 1,086SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesRespiratory viral infections research

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Open access

Gupta, Anil, Gonzalez-Rojas, Yaneicy, Juarez, Erick, Crespo Casal, Manuel, Moya, Jaynier, Falci, Diego R., Sarkis, Elias, Solis, Joel, Zheng, Hanzhe, Scott, Nicola, Cathcart, Andrea L., Hebner, Christy M., Sager, Jennifer, Mogalian, Erik, Tipple, Craig, Peppercorn, Amanda, Alexander, Elizabeth, Pang, Phillip S., Free, Almena, Brinson, Cynthia, Aldinger, Melissa, Shapiro, Adrienne E.·2021·New England Journal of Medicine

DOI 10.1056/nejmoa2107934

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization or death in older patients and those with underlying conditions. Sotrovimab is a pan-sarbecovirus monoclonal antibody that was designed to prevent progression of Covid-19 in high-risk patients early in the course of disease. METHODS: In this ongoing, multicenter, double-blind, phase 3 trial, we randomly assigned, in a 1:1 ratio, nonhospitalized patients with symptomatic Covid-19 (≤5 days after the onset of symptoms) and at least one risk factor for disease progression to receive a single infusion of sotrovimab at a dose of 500 mg or placebo. The primary efficacy outcome was hospitalization (for >24 hours) for any cause or death within 29 days after randomization. RESULTS: In this prespecified interim analysis, which included an intention-to-treat population of 583 patients (291 in the sotrovimab group and 292 in the placebo group), 3 patients (1%) in the sotrovimab group, as compared with 21 patients (7%) in the placebo group, had disease progression leading to hospitalization or death (relative risk reduction, 85%; 97.24% confidence interval, 44 to 96; P = 0.002). In the placebo group, 5 patients were admitted to the intensive care unit, including 1 who died by day 29. Safety was assessed in 868 patients (430 in the sotrovimab group and 438 in the placebo group). Adverse events were reported by 17% of the patients in the sotrovimab group and 19% of those in the placebo group; serious adverse events were less common with sotrovimab than with placebo (in 2% and 6% of the patients, respectively). CONCLUSIONS: Among high-risk patients with mild-to-moderate Covid-19, sotrovimab reduced the risk of disease progression. No safety signals were identified. (Funded by Vir Biotechnology and GlaxoSmithKline; COMET-ICE ClinicalTrials.gov number, NCT04545060.).

Integrity signals

Registry

Crossref · 10.1056/nejmoa2107934

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study
Petrilli, C. M., Jones, S. A., Yang, J., Rajagopalan, H., O’Donnell, L., Chernyak, Y., Tobin, K. A., Cerfolio, R. J., François, F., & Horwitz, L. I. (2020) · BMJ · doi:10.1136/bmj.m1966 · Cited by 3,045
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312
Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020
CDC COVID-19 Response Team, CDC COVID-19 Response Team, Bialek, S. R., Boundy, E. O., Bowen, V. B., Chow, N. A., Cohn, A. C., Dowling, N. F., Ellington, S., Gierke, R., et al. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6912e2 · Cited by 2,278
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
Weinreich, D. M., Sivapalasingam, S., Norton, T., Ali, S., Gao, H., Bhore, R., Musser, B. J., Soo, Y., Rofail, D., Im, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035002 · Cited by 1,642
Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19
Liang, W., Liang, H., Ou, L., Chen, B., Chen, A., Li, C., Li, Y., Guan, W., Sang, L., Lu, J., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.2033 · Cited by 1,387
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Chen, P., Nirula, A., Heller, B., Gottlieb, R. L., Boscia, J., Morris, J., Huhn, G., Cardona, J., Mocherla, B., Stosor, V., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2029849 · Cited by 1,282
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
Chen, R. E., Zhang, X., Case, J. B., Winkler, E. S., Liu, Y., VanBlargan, L. A., Liu, J., Errico, J. M., Xie, X., Suryadevara, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01294-w · Cited by 881

Show all 25 references

Sorted by citations

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
Hammond, J., Leister-Tebbe, H., Gardner, A., Abreu, P., Bao, W., Wisemandle, W., Baniecki, M., Hendrick, V. M., Damle, B., Simón-Campos, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2118542 · Cited by 2,323
Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients.
Jayk Bernal, A., Gomes da Silva, M. M., Musungaie, D. B., Kovalchuk, E., Gonzalez, A., Delos Reyes, V., Martín-Quirós, A., Caraco, Y., Williams-Diaz, A., Brown, M. L., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116044 · Cited by 1,857
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
Gottlieb, R., Vaca, C., Paredes, R., Mera, J., Webb, B. J., Perez, G., Oguchi, G., Ryan, P., Nielsen, B. U., Brown, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2116846 · Cited by 1,254
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Cameroni, E., Bowen, J. E., Rosen, L. E., Saliba, C., Zepeda, S. K., Culap, K., Pinto, D., VanBlargan, L. A., Marco, A. D., di Iulio, J., et al. (2021) · Nature · doi:10.1038/s41586-021-04386-2 · Cited by 1,070
Self-citation
The biological and clinical significance of emerging SARS-CoV-2 variants
Tao, K., Tzou, P. L., Nouhin, J., Gupta, R. K., de Oliveira, T., Kosakovsky Pond, S. L., Fera, D., & Shafer, R. W. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00408-x · Cited by 1,009
The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic
Hoffmann, M., Krüger, N., Schulz, S., Cossmann, A., Rocha, C., Kempf, A., Nehlmeier, I., Graichen, L., Moldenhauer, A.-S., Winkler, M. S., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.032 · Cited by 889
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
VanBlargan, L. A., Errico, J. M., Halfmann, P., Zost, S. J., Crowe, J. E., Purcell, L. A., Kawaoka, Y., Corti, D., Fremont, D. H., & Diamond, M. (2022) · Nature Medicine · doi:10.1038/s41591-021-01678-y · Cited by 690
FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation
Junqueira, C., Crespo, Â. C., Ranjbar, S., de Lacerda, L., Lewandrowski, M., Ingber, J., Parry, B. A., Ravid, S., Clark, S. A., Schrimpf, M. R., et al. (2022) · Nature · doi:10.1038/s41586-022-04702-4 · Cited by 699
SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein–ACE2 complex
Mannar, D., Saville, J. W., Zhu, X., Srivastava, S. S., Berezuk, A. M., Tuttle, K. S., Marquez, A. C., Sekirov, I., & Subramaniam, S. (2022) · Science · doi:10.1126/science.abn7760 · Cited by 630
Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
Iketani, S., Mohri, H., Culbertson, B., Hong, S. J., Duan, Y., Luck, M. I., Annavajhala, M. K., Guo, Y., Sheng, Z., Uhlemann, A., et al. (2022) · Nature · doi:10.1038/s41586-022-05514-2 · Cited by 506
SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape
Starr, T. N., Czudnochowski, N., Liu, Z., Zatta, F., Park, Y., Addetia, A., Pinto, D., Beltramello, M., Hernandez, P., Greaney, A. J., et al. (2021) · Nature · doi:10.1038/s41586-021-03807-6 · Cited by 503
Self-citation
mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant
Gruell, H., Vanshylla, K., Tober-Lau, P., Hillus, D., Schommers, P., Lehmann, C., Kurth, F., Sander, L. E., & Klein, F. (2022) · Nature Medicine · doi:10.1038/s41591-021-01676-0 · Cited by 410
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
Westendorf, K., Žentelis, S., Wang, L., Foster, D., Vaillancourt, P., Wiggin, M., Lovett, E., van der Lee, R., Hendle, J., Pustilnik, A., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110812 · Cited by 408
Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses
Pan, H., Peto, R., Restrepo, A. M. H., Préziosi, M., Moorthy, V., Karim, Q. A., Alejandria, M., García, C. H., Kiény, M.-P., Malekzadeh, R., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00519-0 · Cited by 402
Tackling COVID-19 with neutralizing monoclonal antibodies
Corti, D., Purcell, L. A., Snell, G., & Veesler, D. (2021) · Cell · doi:10.1016/j.cell.2021.05.005 · Cited by 386
Antibodies to watch in 2022
Kaplon, H., Chenoweth, A. M., Crescioli, S., & Reichert, J. M. (2022) · mAbs · doi:10.1080/19420862.2021.2014296 · Cited by 347
Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost
Muecksch, F., Wang, Z., Cho, A., Gaebler, C., Ben Tanfous, T., DaSilva, J., Bednarski, E., Ramos, V., Zong, S., Johnson, B., et al. (2022) · Nature · doi:10.1038/s41586-022-04778-y · Cited by 297
Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies
Lempp, F. A., Soriaga, L. B., Montiel-Ruiz, M., Benigni, F., Noack, J., Park, Y., Bianchi, S., Walls, A. C., Bowen, J. E., Zhou, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03925-1 · Cited by 305
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment
Drożdżal, S., Rosik, J., Lechowicz, K., Machaj, F., Szostak, B., Przybyciński, J., Lorzadeh, S., Kotfis, K., Ghavami, S., & Łoś, M. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100794 · Cited by 301
Early Outpatient Treatment for Covid-19 with Convalescent Plasma
Sullivan, D. J., Gebo, K. A., Shoham, S., Bloch, E. M., Lau, B. M., Shenoy, A. G., Mosnaim, G. S., Gniadek, T. J., Fukuta, Y., Patel, B., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2119657 · Cited by 289
Antibodies to combat viral infections: development strategies and progress
Pantaleo, G., Correia, B. E., Fenwick, C. W., Joo, V., & Perez, L. H. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00495-3 · Cited by 298
Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19
Gupta, A. K., Gonzalez‐Rojas, Y., Juarez, E., Casal, M. C., Moya, J., Falci, D. R., Sarkis, E. H., Solis, J., Zheng, H., Scott, N. E., et al. (2022) · JAMA · doi:10.1001/jama.2022.2832 · Cited by 277
Self-citation
SARS-CoV-2 Reinfections: Overview of Efficacy and Duration of Natural and Hybrid Immunity
Pilz, S., Theiler‐Schwetz, V., Trummer, C., Krause, R. G. E., & Ioannidis, J. P. A. (2022) · Environmental Research · doi:10.1016/j.envres.2022.112911 · Cited by 273
Monoclonal antibody therapies against SARS-CoV-2
Focosi, D., McConnell, S. A., Casadevall, A., Cappello, E., Valdiserra, G., & Tuccori, M. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00311-5 · Cited by 274
Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies
Shah, M., & Woo, H. G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.830527 · Cited by 253
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Cameroni, E., Bowen, J. E., Rosen, L. E., Saliba, C., Zepeda, S. K., Culap, K., Pinto, D., VanBlargan, L. A., Marco, A. D., di Iulio, J., et al. (2021) · Nature · doi:10.1038/d41586-021-03825-4 · Cited by 251
Self-citation
Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial
Montgomery, H., Hobbs, R. F., Padilla, F., Arbetter, D. F., Templeton, A., Seegobin, S., Kim, K., Campos, J. A. S., Arends, R. H., Brodek, B. H., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00180-1 · Cited by 222
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans
Loo, Y., McTamney, P. M., Arends, R. H., Gasser, R. A., Abram, M. E., Cheng, L., Diallo, S., Flores, D. J., Bond, N. J., Ren, K., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl8124 · Cited by 221
Mucosal immune response in biology, disease prevention and treatment
Zhou, X., Wu, Y., Zhu, Z., Lu, C., Zhang, C., Zeng, L., Xie, F., Zhang, L., & Zhou, F. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02043-4 · Cited by 230
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022)
Bhimraj, A., Morgan, R. L., Shumaker, A. H., Baden, L. R., Cheng, V. C., Edwards, K. M., Gallagher, J. C., Gandhi, R. T., Muller, W. J., Nakamura, M., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac724 · Cited by 240
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
Fendler, A., de Vries, E. G. E., GeurtsvanKessel, C. H., Haanen, J. B. A. G., Wormann, B. J., Turajlic, S., & von Lilienfeld‐Toal, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00610-8 · Cited by 211
Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial
Self, W. H., Sandkovsky, U., Reilly, C. S., Vock, D. M., Gottlieb, R. L., Mack, M., Golden, K., Dishner, E., Vekstein, A. M., Ko, E. R., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00751-9 · Cited by 202
Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies
Planas, D., Bruel, T., Staropoli, I., Guivel‐Benhassine, F., Porrot, F., Maes, P., Grzelak, L., Prot, M., Mougari, S., Planchais, C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36561-6 · Cited by 199
A roadmap to pulmonary delivery strategies for the treatment of infectious lung diseases
He, S., Gui, J., Xiong, K., Chen, M., Gao, H., & Fu, Y. S. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01307-x · Cited by 188
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations
Grainger, R., Kim, A. H. J., Conway, R. P., Yazdany, J., & Robinson, P. C. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00755-x · Cited by 193
Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use
Rockett, R. J., Basile, K., Maddocks, S., Fong, W., Agius, J. E., Johnson-Mackinnon, J., Arnott, A., Chandra, S., Gall, M., Draper, J. L., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2120219 · Cited by 171
Deep learning guided optimization of human antibody against SARS-CoV-2 variants with broad neutralization
Shan, S., Luo, S., Yang, Z., Hong, J., Su, Y., Ding, F., Fu, L., Li, C., Chen, P., Ma, J., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2122954119 · Cited by 157
COVID-19 therapeutics: Challenges and directions for the future
Robinson, P. C., Liew, D. F. L., Tanner, H. L., Grainger, J. R., Dwek, R. A., Reisler, R. B., Steinman, L., Feldmann, M., Ho, L., Hussell, T., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2119893119 · Cited by 158
Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study
Mukae, H., Yotsuyanagi, H., Ohmagari, N., Doi, Y., Sakaguchi, H., Sonoyama, T., Ichihashi, G., Sanaki, T., Baba, K., Tsuge, Y., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac933 · Cited by 154
Antiviral neutralizing antibodies: from in vitro to in vivo activity
Burton, D. R. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00858-w · Cited by 168
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19
Kreuzberger, N., Hirsch, C., Chai, K. L., Tomlinson, E., Khosravi, Z., Popp, M., Neidhardt, M., Piechotta, V., Salomon, S., Valk, S. J., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013825.pub2 · Cited by 153
COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment
Karoui, K. E., & Vriese, A. S. D. (2022) · Kidney International · doi:10.1016/j.kint.2022.01.022 · Cited by 150
Antibody-mediated neutralization of SARS-CoV-2
Gruell, H., Vanshylla, K., Weber, T., Barnes, C. O., Kreer, C., & Klein, F. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.005 · Cited by 150
Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system
Lewnard, J. A., McLaughlin, J. M., Malden, D. E., Hong, V. X., Puzniak, L., Ackerson, B. K., Lewin, B. J., Kim, J. S., Shaw, S. F., Takhar, H. S., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00118-4 · Cited by 152
Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins
Wang, Z., Muecksch, F., Cho, A., Gaebler, C., Hoffmann, H.-H., Ramos, V., Zong, S., Cipolla, M., Johnson, B., Schmidt, F., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.04.003 · Cited by 145
COVID-19 in patients with hematologic malignancy
Langerbeins, P., & Hallek, M. J. (2022) · Blood · doi:10.1182/blood.2021012251 · Cited by 143
Two Years into the COVID-19 Pandemic: Lessons Learned
da Silva, S. J. R., do Nascimento, J. C. F., Mendes, R. P. G., Guarines, K. M., da Silva, C. T. A., da Silva, P. G., de Magalhães, J. J. F., Vigar, J. R. J., Silva‐Júnior, A., Kohl, A., et al. (2022) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.2c00204 · Cited by 155
Neutralising antibodies predict protection from severe COVID-19
Cromer, D., Steain, M., Reynaldi, A., Schlub, T. E., Sasson, S. C., Kent, S. J., Khoury, D. S., & Davenport, M. P. (2022) · doi:10.1101/2022.06.09.22275942 · Cited by 139
Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?
Kent, S. J., Khoury, D. S., Reynaldi, A., Juno, J. A., Wheatley, A. K., Stadler, E., John Wherry, E., Triccas, J., Sasson, S. C., Cromer, D., et al. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00716-1 · Cited by 139
A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part
Mukae, H., Yotsuyanagi, H., Ohmagari, N., Doi, Y., Imamura, T., Sonoyama, T., Fukuhara, T., Ichihashi, G., Sanaki, T., Baba, K., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00697-22 · Cited by 137
Development of therapeutic antibodies for the treatment of diseases
Wang, Z., Wang, G., Lu, H., Li, H., Tang, M., & Tong, A. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00100-4 · Cited by 146
Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies
Tada, T., Zhou, H., Dcosta, B. M., Samanovic, M. I., Chivukula, V., Herati, R. S., Hubbard, S. R., Mulligan, M. J., & Landau, N. R. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103944 · Cited by 134
SARS-CoV-2 in immunocompromised individuals
DeWolf, S., Laracy, J. C., Perales, M., Kamboj, M., van den Brink, M. R. M., & Vardhana, S. A. (2022) · Immunity · doi:10.1016/j.immuni.2022.09.006 · Cited by 143
Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial
Holland, T. L., Ginde, A. A., Paredes, R., Murray, T. A., Engen, N. W., Grandits, G., Vekstein, A. M., Ivey, N., Mourad, A., Sandkovsky, U., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00215-6 · Cited by 123
Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9)
Cesaro, S., Ljungman, P. T., Mikulska, M., Hirsch, H. H., von Lilienfeld‐Toal, M., Cordonnier, C., Meylan, S., Mehra, V., Styczyński, J., Marchesi, F., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01578-1 · Cited by 120
Multivalent designed proteins neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice
Hunt, A. C., Case, J. B., Park, Y., Cao, L., Wu, K., Walls, A. C., Liu, Z., Bowen, J. E., Yeh, A. H.-W., Saini, S., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn1252 · Cited by 121
Stopping pandemics before they start: Lessons learned from SARS-CoV-2
Edwards, A. M., Baric, R. S., Saphire, E. O., & Ulmer, J. B. (2022) · Science · doi:10.1126/science.abn1900 · Cited by 109
SARS-CoV-2 Antiviral Therapy
Tao, K., Tzou, P. L., Nouhin, J., Bonilla, H. F., Jagannathan, P., & Shafer, R. W. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00109-21 · Cited by 109
The Global Impact of COVID-19 on Solid Organ Transplantation: Two Years Into a Pandemic
Nimmo, A., Gardiner, D. D., Ushiro‐Lumb, I., Ravanan, R., & Forsythe, J. L. R. (2022) · Transplantation · doi:10.1097/tp.0000000000004151 · Cited by 104
Current status of therapeutic monoclonal antibodies against SARS-CoV-2
Kumar, S., Chandele, A., & Sharma, A. K. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009885 · Cited by 104
Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities
Lim, S. C. L., Hor, C. P., Tay, K. H., Jelani, A. M., Tan, W. H., Ker, H. B., Chow, T. S., Zaid, M., Cheah, W. K., Lim, H. H., et al. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.0189 · Cited by 104
An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19
Singh, A. K., Singh, R., Singh, R., & Misra, A. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102396 · Cited by 94
Sulforaphane exhibits antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses in vitro and in mice
Ordoñez, A. A., Bullen, C. K., Villabona-Rueda, A. F., Thompson, E. A., Turner, M. L., Merino, V. F., Yan, Y., Kim, J., Davis, S. L., Komm, O. D., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03189-z · Cited by 88
Real-world experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the omicron surge
Radcliffe, C. V., Palacios, C. F., Azar, M. M., Cohen, E., & Malinis, M. F. (2022) · American Journal of Transplantation · doi:10.1111/ajt.17098 · Cited by 85
Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs
Bastard, P., Vazquez, S. E., Liu, J., Laurie, M. T., Wang, C., Gervais, A., Voyer, T. L., Bizien, L., Zamecnik, C. R., Philippot, Q., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abp8966 · Cited by 86
Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper
Marjot, T., Eberhardt, C. S., Boettler, T., Belli, L. S., Berenguer, M., Buti, M., Jalan, R., Mondelli, M. U., Moreau, R., Shouval, D., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.07.008 · Cited by 84
Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform
Zheng, B., Green, A. C. A., Tazare, J., Curtis, H. J., Fisher, L., Nab, L., Schultze, A., Mahalingasivam, V., Parker, E. P. K., Hulme, W. J., et al. (2022) · BMJ · doi:10.1136/bmj-2022-071932 · Cited by 86
COVID-19 and kidney disease: insights from epidemiology to inform clinical practice
Mahalingasivam, V., Su, G., Iwagami, M., Davids, M. R., Wetmore, J. B., & Nitsch, D. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00570-3 · Cited by 70
A molecular understanding of alphavirus entry and antibody protection
Kim, A. S., & Diamond, M. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00825-7 · Cited by 87
Human neutralizing antibodies to cold linear epitopes and subdomain 1 of the SARS-CoV-2 spike glycoprotein
Bianchini, F., Crivelli, V., Abernathy, M. E., Guerra, C., Palus, M., Muri, J., Marcotte, H., Piralla, A., Pedotti, M., Gasparo, R. D., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.ade0958 · Cited by 88
Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents
Perico, N., Cortinovis, M., Suter, F., & Remuzzi, G. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00433-9 · Cited by 83
Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis
Siemieniuk, R. A., Bartoszko, J. J., Díaz Martinez, J. P., Kum, E., Qasim, A., Zeraatkar, D., Izcovich, A., Mangala, S., Ge, L., Han, M. A., et al. (2021) · BMJ · doi:10.1136/bmj.n2231 · Cited by 79
Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels
ACTIV-3/TICO Bamlanivimab Study Group*, Lundgren, J. D., Grund, B., Barkauskas, C. E., Holland, T. L., Gottlieb, R., Sandkovsky, U., Brown, S. M., Knowlton, K. U., Self, W. H., et al. (2021) · Annals of Internal Medicine · doi:10.7326/m21-3507 · Cited by 78
Multidrug-resistant mutations to antiviral and antibody therapy in an immunocompromised patient infected with SARS-CoV-2
Hirotsu, Y., Kobayashi, H., Kakizaki, Y., Saito, A., Tsutsui, T., Kawaguchi, M., Shimamura, S., Hata, K., Hanawa, S., Toyama, J., et al. (2023) · Med · doi:10.1016/j.medj.2023.08.001 · Cited by 77
Therapeutic Antibodies in Medicine
Sharma, P., Joshi, R. V., Pritchard, R., Xu, K., & Eicher, M. A. (2023) · Molecules · doi:10.3390/molecules28186438 · Cited by 81
SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns
Gruell, H., Vanshylla, K., Korenkov, M., Tober‐Lau, P., Zehner, M., Münn, F., Janicki, H., Augustin, M., Schommers, P., Sander, L. E., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.07.002 · Cited by 77
Therapeutic monoclonal antibodies for COVID-19 management: an update
Chavda, V. P., Prajapati, R., Lathigara, D., Nagar, B., Kukadiya, J., Redwan, E. M. M. M., Uversky, V. N., Kher, M. N., & Patel, R. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2078160 · Cited by 74
An overview on the treatments and prevention against COVID-19
Panahi, Y., Gorabi, A. M., Talaei, S., Beiraghdar, F., Akbarzadeh, A., Tarhriz, V., & Mellatyar, H. (2023) · Virology Journal · doi:10.1186/s12985-023-01973-9 · Cited by 73
Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT)
Lemaitre, F., Grégoire, M., Monchaud, C., Bouchet, S., Saint–Salvi, B., Polard, É., Benaboud, S., Chouchana, L., Cracowski, J., Drici, M., et al. (2022) · Therapies · doi:10.1016/j.therap.2022.03.005 · Cited by 69
COVID‐19: Omicron – the latest, the least virulent, but probably not the last variant of concern of SARS‐CoV‐2
Brüssow, H. (2022) · Microbial Biotechnology · doi:10.1111/1751-7915.14064 · Cited by 70
Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19Preprint
Dougan, M. L., Azizad, M., Chen, P., Feldman, B., Frieman, M. B., Igbinadolor, A., Kumar, P. N., Morris, J., Potts, J., Baracco, L., et al. (2022) · medRxiv · doi:10.1101/2022.03.10.22272100 · Cited by 70
COVID-19 Therapeutics for Nonhospitalized Patients
Gandhi, R. T., Malani, P., & del Rı́o, C. (2022) · JAMA · doi:10.1001/jama.2022.0335 · Cited by 67
Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19
Johnson, M. G., Puenpatom, A., Moncada, P. A., Burgess, L. J., Duke, E. R., Ohmagari, N., Wolf, T., Bassetti, M., Bhagani, S., Ghosn, J., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m22-0729 · Cited by 67
Endothelial Dysfunction in COVID-19: Potential Mechanisms and Possible Therapeutic Options
Pelle, M. C., Zaffina, I., Lucà, S., Forte, V., Trapanese, V., Melina, M., Giofrè, F., & Arturi, F. (2022) · Life · doi:10.3390/life12101605 · Cited by 72
Mesenchymal stem cell treatment for COVID-19
Xu, R., Feng, Z., & Wang, F. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103920 · Cited by 66
Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses
White, J. M., Schiffer, J. T., Bender Ignacio, R. A., Xu, S., Kainov, D., Ianevski, A., Aittokallio, T., Frieman, M., Olinger, G. G., & Polyak, S. J. (2021) · mBio · doi:10.1128/mbio.03347-21 · Cited by 64
Pharmacological treatment of COVID-19: an opinion paper
García‐Lledó, A., Gómez‐Pavón, J., del Castillo, J. M. G., Hernández‐Sampelayo, T., Delgado, M. C. M., Martín‐Sánchez, F. J., Martínez‐Sellés, M., Molero, J., Guillén, S. M., Rodríguez‐Artalejo, F., et al. (2021) · Revista Española de Quimioterapia · doi:10.37201/req/158.2021 · Cited by 63
Universal healthcare as pandemic preparedness: The lives and costs that could have been saved during the COVID-19 pandemic
Galvani, A. P., Parpia, A. S., Pandey, A., Sah, P., Colon, K., Friedman, G. C., Campbell, T., Kahn, J. G., Singer, B. H., & Fitzpatrick, M. C. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2200536119 · Cited by 62
Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites
Iketani, S., Hong, S. J., Sheng, J., Bahari, F., Culbertson, B., Atanaki, F. F., Aditham, A. K., Kratz, A., Luck, M. I., Tian, R., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.08.003 · Cited by 59
Discovery of highly neutralizing human antibodies targeting Pseudomonas aeruginosa
Simonis, A., Kreer, C., Albus, A., Rox, K., Yuan, B., Holzmann, D., Wilms, J. A., Zuber, S., Kottege, L., Winter, S., et al. (2023) · Cell · doi:10.1016/j.cell.2023.10.002 · Cited by 62
Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies
Bruel, T., Stéfic, K., Nguyen, Y., Toniutti, D., Staropoli, I., Porrot, F., Guivel‐Benhassine, F., Bolland, W., Planas, D., Hadjadj, J., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100850 · Cited by 62
Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy
Ragonnet‐Cronin, M., Nutalai, R., Huo, J., Dijokaite-Guraliuc, A., Das, R., Tuekprakhon, A., Supasa, P., Liu, C., Selvaraj, M., Groves, N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37826-w · Cited by 61
Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients
Haggenburg, S., Lissenberg-Witte, B. I., van Binnendijk, R. S., den Hartog, G., Bhoekhan, M. S., Haverkate, N. J. E., de Rooij, D. M., van Meerloo, J., Cloos, J. J., Kootstra, N. A., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006917 · Cited by 59
The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19
ACTIV-3/TICO Study Group, Rogers, A. J., Wentworth, D. N., Phillips, A. N., Shaw‐Saliba, K., Dewar, R. L., Aggarwal, N. R., Babiker, A. G., Chang, W., Dharan, N. J., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m22-0924 · Cited by 60
High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial
Buonfrate, D., Chesini, F., Martini, D., Roncaglioni, M. C., Fernandez, M. L. O., Alvisi, M. F., Simone, I. D., Rulli, E., Nobili, A., Casalini, G., et al. (2022) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2021.106516 · Cited by 60
In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate
Touret, F., Baronti, C., Bouzidi, H. S., & de Lamballerie, X. N. (2022) · Scientific Reports · doi:10.1038/s41598-022-08559-5 · Cited by 59
The Impact of Vaccination on Incidence and Outcomes of SARS-CoV-2 Infection in Patients with Kidney Failure in Scotland
Bell, S., Campbell, J., Lambourg, E., Watters, C., O’Neil, M., Almond, A., Buck, K., Carr, E. J., Clark, L., Cousland, Z., et al. (2022) · Journal of the American Society of Nephrology · doi:10.1681/asn.2022010046 · Cited by 56
Sotrovimab: First Approval
Heo, Y. (2022) · Drugs · doi:10.1007/s40265-022-01690-7 · Cited by 56
Diagnosis and management of covid-19 in pregnancy
Nana, M., Hodson, K. K., Lucas, N., Camporota, L., Knight, M., & Nelson‐Piercy, C. (2022) · BMJ · doi:10.1136/bmj-2021-069739 · Cited by 56
Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications
Abebe, E. C., & Dejenie, T. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1055457 · Cited by 58

Authors: Gupta, A., Gonzalez-Rojas, Y., Juarez, E., Crespo Casal, M., Moya, J., Falci, D. R., Sarkis, E., Solis, J., Zheng, H., Scott, N., Cathcart, A. L., Hebner, C. M., Sager, J., Mogalian, E., Tipple, C., Peppercorn, A., Alexander, E., Pang, P. S., Free, A., Brinson, C., Aldinger, M., & Shapiro, A. E.
Affiliations: William Osler Health System (CA)
From the Albion Finch Medical Centre, William Osler Health Centre, Toronto (A.G.); Optimus U (Y.G.-R.) and Florida International Medical Research (E.J.), Miami, Pines Care Research Center, Pembroke Pines (J.M.), and Sarkis Clinical Trials, Gainesville (E.S.) — all in Florida; Álvaro Cunqueiro Hospital, IIS Galicia Sur, Vigo, Spain (M.C.C.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (D.R.F.); Centex Studies, McAllen (J. Solis), and Central Texas Clinical Research, Austin (C.B.) — both in Texas; Vir Biotechnology, San Francisco (H.Z., A.L.C., C.M.H., J. Sager, E.M., E.A., P.S.P., M.A.); GlaxoSmithKline, Stevenage, United Kingdom (N.S., C.T.); GlaxoSmithKline, Cambridge, MA (A.P.); Pinnacle Research Group, Anniston, AL (A.F.); and the Departments of Global Health and Medicine, University of Washington, and Fred Hutchinson Cancer Research Center, Seattle (A.E.S.).
Hospital de Clínicas de Porto Alegre (BR)
The University of Texas at Austin (US)
VIR Biotechnology (United States) (US)
GlaxoSmithKline (United Kingdom) (GB)
GlaxoSmithKline (United States) (US)
University of Washington (US)
Corresponding author: Shapiro, Adrienne E.
ORCID: Pang, Phillip S.
Shapiro, Adrienne E.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2021-11-18
Volume: 385
Issue: 21
Pages: 1941-1950
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa2107934
OpenAlex: W3208080692
Cited by: 1,086
References: 25
Citations by year: 2026: 25 · 2025: 72 · 2024: 119 · 2023: 294 · 2022: 509 · 2021: 62
FWCI: 78.13
Type: journal article
Language: en
Open access: green
doi.org
Licence: cc-by-nc-nd
www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
medRxiv (acceptedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Funders: Vir Biotechnology, Inc., in collaboration with GlaxoSmithKline
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
Keywords: sotrovimab, COVID-19 pandemic, SARS-CoV-2, neutralizing monoclonal antibodies, early treatment, disease progression, hospitalization, mortality, high-risk patients, non-hospitalized patients, presymptomatic treatment, adverse events
MeSH terms: SARS-CoV-2, COVID-19 Drug Treatment, Adult, Aged, Ambulatory Care, Double-Blind Method, Female, Hospitalization, Humans, Infusions, Intravenous, Length of Stay, Male, Middle Aged, Incidence, Disease Progression, Antibodies, Neutralizing, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks